Cargando…
DNA Methylation and the HOXC6 Paradox in Prostate Cancer
Overexpression of the classical homeobox transcription factor HOXC6 is frequent in prostate cancers and correlates with adverse clinical parameters. Since surprisingly many HOXC6 target genes are downregulated in prostate cancer, it has been posited that oncogenic effects of HOXC6 in prostate cancer...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Molecular Diversity Preservation International (MDPI)
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3763392/ https://www.ncbi.nlm.nih.gov/pubmed/24213107 http://dx.doi.org/10.3390/cancers3043714 |
_version_ | 1782283006311923712 |
---|---|
author | Vinarskaja, Anna Yamanaka, Masanori Ingenwerth, Marc Schulz, Wolfgang A. |
author_facet | Vinarskaja, Anna Yamanaka, Masanori Ingenwerth, Marc Schulz, Wolfgang A. |
author_sort | Vinarskaja, Anna |
collection | PubMed |
description | Overexpression of the classical homeobox transcription factor HOXC6 is frequent in prostate cancers and correlates with adverse clinical parameters. Since surprisingly many HOXC6 target genes are downregulated in prostate cancer, it has been posited that oncogenic effects of HOXC6 in prostate cancer may be unmasked by concurrent epigenetic downregulation of target genes exerting tumor suppressive effects. To test this hypothesis, we have studied the expression of three HOXC6 target genes, CNTN1 (encoding a cell adhesion protein), DKK3 and WIF1 (encoding WNT growth factor antagonists) as well as DNA methylation of DKK3 and WIF1. HOXC6 upregulation and association with poor prognosis were confirmed in our tissue series. The three target genes were each significantly downregulated in cancer tissues and expression of each one correlated inversely with that of HOXC6. Cases with lower WIF1 expression showed significantly earlier recurrence (p = 0.021), whereas no statistical significance was reached for CNTN1 and DKK3. Hypermethylation of DKK3 or WIF1 gene promoters was observed in a subset of cancers with downregulated expression, but was often weak. Our data support the hypothesis that HOXC6 target genes exerting tumor-suppressive effects are epigenetically downregulated in prostate cancer, but DNA methylation appears to follow or bolster rather than to cause their transcriptional inactivation. |
format | Online Article Text |
id | pubmed-3763392 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | Molecular Diversity Preservation International (MDPI) |
record_format | MEDLINE/PubMed |
spelling | pubmed-37633922013-09-05 DNA Methylation and the HOXC6 Paradox in Prostate Cancer Vinarskaja, Anna Yamanaka, Masanori Ingenwerth, Marc Schulz, Wolfgang A. Cancers (Basel) Article Overexpression of the classical homeobox transcription factor HOXC6 is frequent in prostate cancers and correlates with adverse clinical parameters. Since surprisingly many HOXC6 target genes are downregulated in prostate cancer, it has been posited that oncogenic effects of HOXC6 in prostate cancer may be unmasked by concurrent epigenetic downregulation of target genes exerting tumor suppressive effects. To test this hypothesis, we have studied the expression of three HOXC6 target genes, CNTN1 (encoding a cell adhesion protein), DKK3 and WIF1 (encoding WNT growth factor antagonists) as well as DNA methylation of DKK3 and WIF1. HOXC6 upregulation and association with poor prognosis were confirmed in our tissue series. The three target genes were each significantly downregulated in cancer tissues and expression of each one correlated inversely with that of HOXC6. Cases with lower WIF1 expression showed significantly earlier recurrence (p = 0.021), whereas no statistical significance was reached for CNTN1 and DKK3. Hypermethylation of DKK3 or WIF1 gene promoters was observed in a subset of cancers with downregulated expression, but was often weak. Our data support the hypothesis that HOXC6 target genes exerting tumor-suppressive effects are epigenetically downregulated in prostate cancer, but DNA methylation appears to follow or bolster rather than to cause their transcriptional inactivation. Molecular Diversity Preservation International (MDPI) 2011-09-27 /pmc/articles/PMC3763392/ /pubmed/24213107 http://dx.doi.org/10.3390/cancers3043714 Text en © 2011 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/). |
spellingShingle | Article Vinarskaja, Anna Yamanaka, Masanori Ingenwerth, Marc Schulz, Wolfgang A. DNA Methylation and the HOXC6 Paradox in Prostate Cancer |
title | DNA Methylation and the HOXC6 Paradox in Prostate Cancer |
title_full | DNA Methylation and the HOXC6 Paradox in Prostate Cancer |
title_fullStr | DNA Methylation and the HOXC6 Paradox in Prostate Cancer |
title_full_unstemmed | DNA Methylation and the HOXC6 Paradox in Prostate Cancer |
title_short | DNA Methylation and the HOXC6 Paradox in Prostate Cancer |
title_sort | dna methylation and the hoxc6 paradox in prostate cancer |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3763392/ https://www.ncbi.nlm.nih.gov/pubmed/24213107 http://dx.doi.org/10.3390/cancers3043714 |
work_keys_str_mv | AT vinarskajaanna dnamethylationandthehoxc6paradoxinprostatecancer AT yamanakamasanori dnamethylationandthehoxc6paradoxinprostatecancer AT ingenwerthmarc dnamethylationandthehoxc6paradoxinprostatecancer AT schulzwolfganga dnamethylationandthehoxc6paradoxinprostatecancer |